The U.S. Food and Drug Administration has approved Merck & Co.’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), a subcutaneous injection for adult patients across most solid tumor indications previously approved for KEYTRUDA (pembrolizumab). The new formulation, which combines pembrolizumab with berahyaluronidase alfa, a human hyaluronidase variant developed by Alteogen Inc., must be administered by health care providers. Merck expects KEYTRUDA QLEX to be available in the U.S...